BiotechTube

Imiquimod 5 % Cream

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Nov 1, 2002 → Sep 1, 2005

NCT ID
NCT00189267

About Imiquimod 5 % Cream

Imiquimod 5 % Cream is a phase 2 stage product being developed by Viatris for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00189267. Target conditions include Actinic Keratosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00189267Phase 2Completed

Competing Products

20 competing products in Actinic Keratosis

See all competitors
ProductCompanyStageHype Score
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
33
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
33
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
33
Investigational Treatment + Active comparatorNovartisPhase 2
52
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
76
FluorouracilSanofiPhase 1/2
40
fluorouracil cream 0.5%SanofiApproved
84
Imiquimod + DiclofenacViatrisApproved
82
ImiquimodViatrisPre-clinical
20
Aldara (Imiquimod)ViatrisPhase 3
74
Imiquimod + DiclofenacViatrisApproved
82
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice dailyDr. Reddy's LaboratoriesPhase 2/3
62
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
72
5-fluorouracil/salicylic acid + VehicleAlmirallPhase 3
72
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
47
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
80
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
72
Tirbanibulin 2.5 mg ointmentAlmirallApproved
80

Other Products from Viatris

Revefenacin + Tiotropium + Revefenacin Placebo + Tiotropium PlaceboApproved
82
PregabalinApproved
82
Imiquimod + DiclofenacApproved
82
gabapentin 600 mg + gabapentin 1200 mg + gabapentin 1800 mg + diazepam 20 mgApproved
82
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsApproved
82